Skip to content

C83.70

Billable

Burkitt lymphoma, unspecified site

Last updated: FY2026 ICD-10-CM (Oct 1, 2025 – Sep 30, 2026) | CMS-HCC V28 (100% phase-in, PY2026)

Is C83.70 an HCC code?

Yes. C83.70 maps to Lung and Other Severe Cancers under the CMS-HCC V28 risk adjustment model (and Lymphoma and Other Cancers under V24).

HCC Category Mapping

V28HCC 20Lung and Other Severe Cancers
1.136
V24HCC 10Lymphoma and Other Cancers
0.675
ESRDHCC 10Lymphoma and Other Cancers
0.111
RxHCCHCC 21Lymphomas and Other Hematologic Cancers
0.410

RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.

MEAT Criteria for C83.70

For C83.70to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically — it has to be re-documented and supported each calendar year.

  • MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
  • EEvaluate: test results, medication response, or physical findings reviewed by the provider
  • AAssess: explicit mention in the assessment or plan with acknowledgment of status
  • TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis

Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed C83.70 during that encounter — not just copy-forwarded from a problem list.

What This Code Means

C83.70 is the ICD-10-CM diagnosis code for burkitt lymphoma, unspecified site. Burkitt lymphoma, an aggressive type of blood cancer, when the specific location of the lymph nodes involved is not specified or documented. C83.70 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neoplasms of lymphoid, hematopoietic and related tissue (c81-c96).

Under the CMS-HCC V28 risk adjustment model, C83.70 maps to Lung and Other Severe Cancers (HCC 20) with a community, non-dual, aged base RAF weight of 1.136. Under the older CMS-HCC V24 model, C83.70 maps to Lymphoma and Other Cancers (HCC 10) with a community, non-dual, aged base RAF weight of 0.675. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.

Use this code only when the site of involvement is unknown or not documented; always attempt to identify the specific site. Because C83.70 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.

HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for C83.70 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.

Coding Tips

  • Use this code only when the site of involvement is unknown or not documented; always attempt to identify the specific site
  • Review imaging reports and pathology documentation to determine if a more specific site code (C83.71-C83.77) should be used instead

Clinical Significance

Burkitt lymphoma is one of the most aggressive human malignancies with an extremely high proliferation rate (Ki-67 approaching 100%). It has three clinical variants: endemic (African, jaw involvement), sporadic (abdominal masses), and immunodeficiency-associated (HIV). The unspecified site code should be used only when documentation does not identify the involved anatomical site.

Documentation Requirements

  • Pathology confirmation showing 'starry sky' pattern with high Ki-67 (near 100%)
  • FISH demonstrating MYC (c-MYC) translocation, typically t(8;14)
  • Immunohistochemistry panel (CD20+, CD10+, BCL6+, BCL2-, TdT-)
  • HIV testing and EBV status
  • Tumor lysis syndrome risk assessment (LDH, uric acid, potassium, phosphorus, calcium)
  • Staging with assessment for CNS and bone marrow involvement

Commonly Confused Codes

  • C83.30 — Diffuse large B-cell lymphoma, unspecified; DLBCL is the most important differential; BCL2 negativity and 100% Ki-67 favor Burkitt
  • C83.50 — Lymphoblastic lymphoma, unspecified; lymphoblastic is TdT+ (immature), Burkitt is TdT- (mature)
  • C85.10 — Unspecified non-Hodgkin lymphoma; always use Burkitt-specific code when pathology confirms the diagnosis
  • C83.80 — Other non-follicular lymphoma; Burkitt-like or atypical Burkitt may overlap; requires molecular studies

Code Hierarchy

Open C83.70 in the Interactive Encoder

See full code details, AI coding tips, HCC mappings, and related codes in our interactive encoder. Start your 14-day Pro trial — no credit card required.